| Multiple epiphyseal dysplasia |
| Classification and external resources |
| ICD-10 |
Q78.8 |
| ICD-9 |
756.56 |
| OMIM |
132400 600204 600969 226900 607078 120210 |
| DiseasesDB |
30716 |
| eMedicine |
article/1259038 |
| MeSH |
D010009 |
| GeneReviews |
- Multiple Epiphyseal Dysplasia, Dominant
- Multiple Epiphyseal Dysplasia, Recessive
|
Fairbanks disease or multiple epiphyseal dysplasia (MED) is a rare genetic disorder (dominant form—1 in 10,000 births) which affects the growing ends of bones. Bones usually elongate by a process that involves the depositing of cartilage at the ends of the bones, called ossification. This cartilage then mineralizes and hardens to become bone. In MED, this process is defective.
|
Contents
- 1 Inheritance
- 2 Signs and Symptoms
- 3 Discovery
- 4 Cause
- 5 Diagnosis
- 6 Treatment
- 7 Prominent people with this condition
- 8 References
- 9 External links
|
Inheritance
Multiple epiphyseal dysplasia (MED) encompasses a spectrum of skeletal disorders, most of which are inherited in an autosomal dominant form. However, there is also an autosomal recessive form.
Associated genes include COL9A2, COL9A3, COMP, and MATR3.[1]
Types include:
| Type |
OMIM |
Gene |
| EDM1 |
132400 |
COMP |
| EDM2 |
600204 |
COL9A2 |
| EDM3 |
600969 |
COL9A3 |
| EDM4 |
226900 |
DTDST |
| EDM5 |
607078 |
MATN3 |
| EDM6 |
120210 |
COL9A1 |
Signs and Symptoms
Children with autosomal dominant MED experience joint pain and fatigue after exercising. Their x-rays show small and irregular ossifications centers, most apparent in the hips and knees. A waddling gait may develop. Flat feet are very common.[2] The spine is normal but may have a few irregularities, such as scoliosis. There are very small capital femoral epiphyses and hypoplastic, poorly formed acetabular roofs. Knees have metaphyseal widening and irregularity while hands have brachydactyly (short fingers) and proximal metacarpal rounding. By adulthood, people with MED are of short stature or in the low range of normal and have short limbs relative to their trunks. Frequently, movement becomes limited at the major joints, especially at the elbows and hips. However, loose knee and finger joints can occur. Signs of osteoarthritis usually begin in early adulthood.[3]
Children with recessive MED also experience joint pain, particularly of the hips and knees, but also commonly have deformities of the hands, feet, knees, or vertebral column (like scoliosis). Approximately 50% of affected children have abnormal findings at birth (e.g., club foot or twisted metatarsals, cleft palate, inward curving fingers due to underdeveloped bones and brachydactyly, or ear swelling caused by injury during birth). Height is within the normal range prior to puberty. As adults, people with recessive MED are only slightly more diminished in stature but still within the normal range. Lateral knee radiography can show multi-layered patellae.[3]
Discovery
Multiple epiphyseal dysplasia was described separately by Ribbing and Fairbank in the 1930s.[3]
In 1994, Ralph Oehlmann's group mapped MED to the peri-centromeric region of chromosome 19, using genetic linkage analysis.[4] Michael Briggs' group mapped PSACH to the same area.[5] COMP gene was fistly linked to MED and PSACH in 1995.[6] Later on, in 1995, the group led by Knowlton did a "high-resolution genetic and physical mapping of multiple epiphyseal dysplasia and pseudoachondroplasia mutations at chromosome 19p13.1-p12".[7] Research on COMP led to mouse models of the pathology of MED. In 2002, Svensson's group generated a COMP-null mouse to study the COMP protein in vivo. However, these mice showed no anatomical, histological, or even ultrastructural abnormalities and none of the clinical signs of PSACH or MED. Lack of COMP was not compensated for by any other protein in the thrombospondin family. This study confirmed that the disease is not caused by reduced expression of COMP.[8] In 2007, Piròg-Garcia's group generated another mouse model carrying a mutation previously found in a human patient. With this new model, they were able to demonstrate that reduced cell proliferation and increased apoptosis are significant pathological mechanisms involved in MED and PSACH.[9] In 2010, this mouse model allowed a new insight into myopathy and tendinopathy, which are often associated with PSACH and MED. These patients show increased skeletal muscle stress, as indicated by the increase in myofibers with central nuclei). Myopathy in the mutant mouse results from underlying tendinopathy, because the transmission of forces is altered from the normal state. There is a higher proportion of larger diameter fibrils of collagen but the cross-sectional area of whole mutant tendons was also significantly less than that of the wild-type tendons causing joint laxity and stiffness, easy tiringness and weakness. This study is important because those diseases are often mistaken for neurological problems, since the doctor can detect a muscle weakness. This include a lot of painful and useless clinical neurological examination prior to the correct diagnosis. In this work, the researchers suggest to the pediatric doctor to perform x-rays before starting the neurological assessment, to exclude the dysplasia.[10]
COL91A mutation was discovered in 2001.[1]
Cause
In the dominant form, mutations in five genes are causative: COMP (chromosome 19), COL9A1 (chromosome 6), COL9A2 (chromosome 1), COL9A3 (chromosome 20), and MATN3 (chromosome 2). However, in approximately 10%-20% of all samples analyzed, a mutation cannot be identified in any of the five genes above, suggesting that mutations in other as-yet unidentified genes are also involved in the pathogenesis of dominant MED.[11] The COMP gene is mutated in 70% of the molecularly confirmed MED patients. Mutations are located in the exons encoding the type III repeats (exons 8-14) and C-terminal domain (exons 15-19).[12] The most common mutations in COL9A1 are located in exons 8-10, in COL9A2 in exons 2-4, and in COL9A3 in exons 2-4. Altogether, those mutations cover 10% of the patients. Other 20% of affected people have mutations in MATN3 gene, all found within exon 2. In order to this findings, the following testing regime has been recommended by the European Skeletal Dysplasia Network:
- Level 1: COMP (exons 10-15) and MATN3 (exon 2)
- Level 2: COMP (exons 8 & 9 and 16-19)
- Level 3: COL9A1 (exon 8), COL9A2 and COL9A3 (exon 3)
All those genes are involved in the production of the extracellular matrix (ECM). The role of COMP gene still remains unclear. It is a noncollagenous protein of the ECM.[13] Mutations in this gene can also cause the pseudoachondroplasia (PSACH). It should play a role in the structural integrity of cartilage via its interaction with other extracellular matrix proteins and can be part of the interaction of the chondrocytes with the matrix through. It is a potent suppressor of apoptosis in chondrocytes and can suppress apoptosis. Another one of it roles is maintaining a vascular smooth muscle cells contractile under physiological or pathological stimuli[14] Since 2003, the European Skeletal Dysplasia Network has used an on-line system to do diagnose cases referred to the network prior to mutation analysis in order to study the different mutations causing PSACH or MED.[15]
COL9A1, COL9A2, COL9A3 are genes coding for collagen type IX, that is a component of hyaline cartilage. MATN3 protein may play a role in the formation of the extracellular filamentous networks and in the development and homeostasis of cartilage and bone.[16]
In the recessive form, DTDST gene is mutated almost in 90% of the patients. It is also known as SLC26A2. It is a sulfate transporter, transmembrane glycoprotein implicated in several chondrodysplasias. It is important for sulfation of proteoglycans and matrix organization.[17]
Diagnosis
Diagnosis should be based on the clinical and radiographic findings and a genetical analysis can be assessed.[18]
Treatment
Symptomatic individuals should be seen by an orthopedist in order to assess the possibility of treatment (physiotherapy for muscular strengthening, cautious use of analgesic medications such as nonsteroidal anti-inflammatory drugs). Although there is no cure, surgery is sometimes used to relieve symptoms.[19] Surgery may be necessary to treat malformation of the hip (osteotomy of the pelvis or the collum femoris) and, in some cases, malformation (e.g., genu varum or genu valgum).[20] In some cases, total hip replacement may be necessary. However, surgery is not always necessary or appropriate.[21] Sports involving joint overload are to be avoided, while swimming or cycling are strongly suggested.[22] Indoor cycling has to be avoided in people having ligamentous laxity. Weight control is suggested.[23] The use of crutches, other deambulatory aids or wheelchair is useful to prevent hip pain.[24] Pain in the hand while writing can be avoided using a pen with wide grip.[25]
Prominent people with this condition
- Robert Reich,[26] American economist who served as the Secretary of Labor under President Bill Clinton from 1993–1997.
- Danny DeVito, American actor and comedian.
- David Wetherill, British Paralympian table tennis athlete.[27]
References
- ^ a b Czarny-Ratajczak M, Lohiniva J, Rogala P, et al. (November 2001). "A mutation in COL9A1 causes multiple epiphyseal dysplasia: further evidence for locus heterogeneity". Am. J. Hum. Genet. 69 (5): 969–80. doi:10.1086/324023. PMC 1274373. PMID 11565064. http://linkinghub.elsevier.com/retrieve/pii/S0002-9297(07)61313-5.
- ^ Kozlowski, Giuseppe Canepa, Pierre Maroteaux, Vincenzo Pietrogrande ; histopatological atlas: V. Stanescu, R. Stanescu ; foreword by K.S. (2001). Dysmorphic-syndromes and constitutional diseases of the skeleton : atlas with computer programme for finding symptoms and making diagnoses. Padova: Piccin. ISBN 978-8829915026.
- ^ a b c Lachman RS, Krakow D, Cohn DH, Rimoin DL (2005). "MED, COMP, multilayered and NEIN: an overview of multiple epiphyseal dysplasia.". Pediatr Radiol 35 (2): 116–23. doi:10.1007/s00247-004-1323-4. PMID 15503005.
- ^ Oehlmann R, Summerville GP, Yeh G, Weaver EJ, Jimenez SA, Knowlton RG (1994). "Genetic linkage mapping of multiple epiphyseal dysplasia to the pericentromeric region of chromosome 19.". Am J Hum Genet 54 (1): 3–10. PMC 1918067. PMID 8279467. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1918067/.
- ^ Briggs MD, Rasmussen IM, Weber JL, Yuen J, Reinker K, Garber AP et al. (1993). "Genetic linkage of mild pseudoachondroplasia (PSACH) to markers in the pericentromeric region of chromosome 19.". Genomics 18 (3): 656–60. doi:10.1016/S0888-7543(05)80369-6. PMID 8307576.
- ^ Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG et al. (1995). "Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene.". Nat Genet 10 (3): 330–6. doi:10.1038/ng0795-330. PMID 7670472.
- ^ Knowlton RG, Cekleniak JA, Cohn DH, Briggs MD, Hoffman SM, Brandriff BF et al. (1995). "High-resolution genetic and physical mapping of multiple epiphyseal dysplasia and pseudoachondroplasia mutations at chromosome 19p13.1-p12.". Genomics 28 (3): 513–9. doi:10.1006/geno.1995.1183. PMID 7490089. http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7490089.
- ^ Svensson L, Aszódi A, Heinegård D, Hunziker EB, Reinholt FP, Fässler R et al. (2002). "Cartilage oligomeric matrix protein-deficient mice have normal skeletal development.". Mol Cell Biol 22 (12): 4366–71. PMC 133870. PMID 12024046. //www.ncbi.nlm.nih.gov/pmc/articles/PMC133870/.
- ^ Piróg-Garcia KA, Meadows RS, Knowles L, Heinegård D, Thornton DJ, Kadler KE et al. (2007). "Reduced cell proliferation and increased apoptosis are significant pathological mechanisms in a murine model of mild pseudoachondroplasia resulting from a mutation in the C-terminal domain of COMP.". Hum Mol Genet 16 (17): 2072–88. doi:10.1093/hmg/ddm155. PMC 2674228. PMID 17588960. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2674228/.
- ^ Piróg KA, Jaka O, Katakura Y, Meadows RS, Kadler KE, Boot-Handford RP et al. (2010). "A mouse model offers novel insights into the myopathy and tendinopathy often associated with pseudoachondroplasia and multiple epiphyseal dysplasia.". Hum Mol Genet 19 (1): 52–64. doi:10.1093/hmg/ddp466. PMC 2792148. PMID 19808781. http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19808781.
- ^ , PMID 20301302
- ^ Briggs MD, Chapman KL (2002). "Pseudoachondroplasia and multiple epiphyseal dysplasia: mutation review, molecular interactions, and genotype to phenotype correlations.". Hum Mutat 19 (5): 465–78. doi:10.1002/humu.10066. PMID 11968079.
- ^ Paulsson M, Heinegård D (1981). "Purification and structural characterization of a cartilage matrix protein.". Biochem J 197 (2): 367–75. PMC 1163135. PMID 7325960. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1163135/.
- ^ "GeneCards". http://www.genecards.org/cgi-bin/carddisp.pl?id_type=entrezgene&id=1311.
- ^ Jackson GC, Mittaz-Crettol L, Taylor JA, Mortier GR, Spranger J, Zabel B et al. (2012). "Pseudoachondroplasia and multiple epiphyseal dysplasia: a 7-year comprehensive analysis of the known disease genes identify novel and recurrent mutations and provides an accurate assessment of their relative contribution.". Hum Mutat 33 (1): 144–57. doi:10.1002/humu.21611. PMC 3272220. PMID 21922596. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3272220/.
- ^ "MATN3 review". http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=full_report&list_uids=4148.
- ^ "SLC26A2 solute carrier family 26". http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=full_report&list_uids=1836.
- ^ Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-.
- ^ Trehan R, Dabbas N, Allwood D, Agarwal M, Kinmont C (2008). "Arthroscopic decompression and notchplasty for long-standing anterior cruciate ligament impingement in a patient with multiple epiphyseal dysplasia: a case report". J Med Case Reports 2: 172. doi:10.1186/1752-1947-2-172. PMC 2412893. PMID 18498631. http://www.jmedicalcasereports.com/content/2//172.
- ^ Linden, Suzanne K. Campbell, Robert J. Palisano, Darl W. Vander (2005). Physical therapy for children (3rd ed. ed.). Philadelphia, Pa.: Elsevier Saunders. ISBN 9780721603780.
- ^ Bajuifer S, Letts M (April 2005). "Multiple epiphyseal dysplasia in children: beware of overtreatment!". Can J Surg 48 (2): 106–9. PMID 15887789. http://www.cma.ca/multimedia/staticContent/HTML/N0/l2/cjs/vol-48/issue-2/pdf/pg106.pdf.
- ^ Juergen Maeurer (2006). Imaging strategies for the knee. ISBN 3131405619 9783131405616 1588904490 9781588904492.
- ^ Paans N, van den Akker-Scheek I, van der Meer K, Bulstra SK, Stevens M (2009). "The effects of exercise and weight loss in overweight patients with hip osteoarthritis: design of a prospective cohort study.". BMC Musculoskelet Disord 10: 24. doi:10.1186/1471-2474-10-24. PMC 2649885. PMID 19236692. http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19236692.
- ^ L.Echternach, Ed.John (1990). Physical therapy of the hip. New York...[etc.]: Churchill Livingstone. ISBN 978-0443086502.
- ^ . ISBN 978-1848826106.
- ^ Leibovitch, Mark (March 14, 2002). "The True Measure of a Man". The Washington Post. Archived from the original on April 23, 2003. Retrieved November 8, 2008.
- ^ David Wetherill; Parasport
External links
- Explanation of Multiple Epiphyseal Dysplasia (MED)
- GeneReview/NIH/UW entry on Multiple Epiphyseal Dysplasia, Dominant
- GeneReview/NIH/UW entry on Multiple Epiphyseal Dysplasia, Recessive
- Video about MED on YouTube
- MED Awareness
- MED Facebook group
|
Osteochondrodysplasia (Q77–Q78, 756.4–756.5)
|
|
Osteodysplasia/
osteodystrophy |
|
Diaphysis
|
Camurati-Engelmann disease
|
|
|
Metaphysis
|
Metaphyseal dysplasia · Jansen's metaphyseal chondrodysplasia · Schmid metaphyseal chondrodysplasia
|
|
|
Epiphysis
|
Spondyloepiphyseal dysplasia congenita · Multiple epiphyseal dysplasia · Otospondylomegaepiphyseal dysplasia
|
|
|
Osteosclerosis
|
Raine syndrome · Osteopoikilosis · Osteopetrosis
|
|
|
Other/ungrouped
|
FLNB (Boomerang dysplasia) · Opsismodysplasia · Polyostotic fibrous dysplasia (McCune-Albright syndrome)
|
|
|
Chondrodysplasia/
chondrodystrophy
(including dwarfism) |
|
Osteochondroma
|
osteochondromatosis (Hereditary multiple exostoses)
|
|
|
Chondroma/enchondroma
|
enchondromatosis (Ollier disease, Maffucci syndrome)
|
|
|
Growth factor receptor
|
FGFR2: Antley-Bixler syndrome
FGFR3: Achondroplasia (Hypochondroplasia) · Thanatophoric dysplasia
|
|
|
COL2A1 collagen disease
|
Achondrogenesis (type 2) · Hypochondrogenesis
|
|
|
SLC26A2 sulfation defect
|
Achondrogenesis (type 1B) · Recessive multiple epiphyseal dysplasia · Atelosteogenesis, type II · Diastrophic dysplasia
|
|
|
Chondrodysplasia punctata
|
Rhizomelic chondrodysplasia punctata · Conradi-Hünermann syndrome
|
|
|
Other dwarfism
|
Fibrochondrogenesis · Short rib-polydactyly syndrome (Majewski's polydactyly syndrome) · Léri-Weill dyschondrosteosis
|
|
|
|
|
anat (c/f/k/f, u, t/p, l)/phys/devp/cell
|
noco/cong/tumr, sysi/epon, injr
|
|
|
|
|
|
Genetic disorder, extracellular: scleroprotein disease (excluding laminin and keratin)
|
|
| Collagen disease |
COL1: Osteogenesis imperfecta · Ehlers–Danlos syndrome, types 1, 2, 7
COL2: Hypochondrogenesis · Achondrogenesis type 2 · Stickler syndrome · Marshall syndrome · Spondyloepiphyseal dysplasia congenita · Spondyloepimetaphyseal dysplasia, Strudwick type · Kniest dysplasia (see also C2/11)
COL3: Ehlers–Danlos syndrome, types 3 & 4 (Sack–Barabas syndrome)
COL4: Alport syndrome
COL5: Ehlers–Danlos syndrome, types 1 & 2
COL6: Bethlem myopathy · Ullrich congenital muscular dystrophy
COL7: Epidermolysis bullosa dystrophica · Recessive dystrophic epidermolysis bullosa · Bart syndrome · Transient bullous dermolysis of the newborn
COL8: Fuchs' dystrophy 1
COL9: Multiple epiphyseal dysplasia 2, 3, 6
COL10: Schmid metaphyseal chondrodysplasia
COL11: Weissenbacher–Zweymüller syndrome · Otospondylomegaepiphyseal dysplasia (see also C2/11)
COL17: Bullous pemphigoid
|
|
| Laminin |
Junctional epidermolysis bullosa · Laryngoonychocutaneous syndrome
|
|
| Other |
Congenital stromal corneal dystrophy · Raine syndrome · Urbach–Wiethe disease · TECTA (DFNA8/12, DFNB21)
|
|
see also fibrous proteins
- B structural
- perx
- skel
- cili
- mito
- nucl
- sclr
- DNA/RNA/protein synthesis
- membrane
- transduction
- trfk
|
|
|
Genetic disorder, membrane: Solute carrier disorders
|
|
| 1-10 |
SLC1A3 (Episodic ataxia 6) · SLC2A1 (De Vivo disease) · SLC2A5 (Fructose malabsorption) · SLC2A10 (Arterial tortuosity syndrome) · SLC3A1 (Cystinuria) · SLC4A1 (Hereditary spherocytosis 4/Hereditary elliptocytosis 4) · SLC4A11 (Congenital endothelial dystrophy type 2, Fuchs' dystrophy 4) · SLC5A1 (Glucose-galactose malabsorption) · SLC5A2 (Renal glycosuria) · SLC5A5 (Thyroid dyshormonogenesis type 1) · SLC6A19 (Hartnup disease) · SLC7A7 (Lysinuric protein intolerance) · SLC7A9 (Cystinuria)
|
|
| 11-20 |
SLC11A1 (Crohn's disease) · SLC12A3 (Gitelman syndrome) · SLC16A1 (HHF7) · SLC16A2 (Allan–Herndon–Dudley syndrome) · SLC17A5 (Salla disease) · SLC17A8 (DFNA25)
|
|
| 21-40 |
SLC26A2 (Multiple epiphyseal dysplasia 4, Achondrogenesis type 1B, Recessive multiple epiphyseal dysplasia, Atelosteogenesis, type II, Diastrophic dysplasia) · SLC26A4 (Pendred syndrome) · SLC35C1 (CDOG 2C) · SLC39A4 (Acrodermatitis enteropathica) · SLC40A1 (African iron overload)
|
|
see also solute carrier family
- B structural
- perx
- skel
- cili
- mito
- nucl
- sclr
- DNA/RNA/protein synthesis
- membrane
- transduction
- trfk
|
|